Abstract
Methods: This study evaluated the effectiveness and morbidity associated with 116 peritoneovenous shunts inserted into 89 patients for symptomatic malignant ascites between 1981 and 1991. All patients had previously failed standard medical therapy of salt and fluid restriction, diuretics, and intermittent peritoneal aspirations.
Results: Symptoms from the ascites included discomfort, impaired mobility, early satiety, and dyspnea. The study population was composed of 31 men and 58 women whose ages ranged from 24 to 81 years (mean 56). Primary tumors originated from the following sites: breast, 17; ovary, 17; pancreas, 13; gastrointestinal or related organs, 21; and other sites, 21. Mean shunt patency was 83 days; however, only 31% of the patients studied maintained a patent shunt and lived for >2 months. Symptomatic relief was achieved in only 57 patients (62%). Forty-four patients (49%) developed one or more complications related to shunt placement. The deaths of 12 patients (13%) within 30 days of surgery were directly related to a complication of shunt placement. Overall, 30- and 60-day mortality rates were 43% and 61%, respectively.
Conclusions: Due to the brief and only fair relief of symptoms with a high associated morbidity and mortality, we believe peritoneovenous shunts are of very limited usefulness in the palliation of malignant ascites and suggest that alternate methods should be considered to manage these patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Straus AK, Roseman DL, Shapiro TM. Peritoneovenous shunting in the management of malignant ascites.Arch Surg 1979;114:489–91.
LeVeen HH, Christoudias G, Ip M, Luff R, Falk G, Grossberg S. Peritoneovenous shunting for ascites.Ann Surg 1974;180:580–91.
Harmon DC, Demirjian Z, Ellman L. Disseminated intravascular coagulation with the peritoneovenous shunt.Ann Intern Med 1979;90:774–6.
Reinhold RB, Lokich JJ, Tomashefski J, Costello P. Management of malignant ascites with peritoneovenous shunting.Am J Surg 1983;145:455–7.
Rubinstein D, McInnes I, Dudley F. Morbidity and mortality after peritoneovenous shunt surgery for refractory ascites.Gut 1985;26:1070–3.
Sonnenfeld T, Tyden G. Peritoneovenous shunts for malignant ascites.Acta Chir Scand 1986;152:117–21.
Osterlee J. Peritoneovenous shunting for ascites in cancer patients.Br J Surg 1980;67:663–6.
Bernhoft RA, Pellegrini CA, Way LW. Peritoneovenous shunt for refractory ascites.Arch Surg 1982;117:631–5.
Souter RG, Wells C, Tarin D, et al. Surgical and pathological complications associated with peritoneovenous shunts in management of malignant ascites.Cancer 1985;55:1973–8.
Lokich J, Reinhold R, Silverman M, Tullis J. Complications of peritoneovenous shunt for malignant ascites.Can Treat Rep 1980;64:305–9.
Qazi R, Savlov ED. Peritoneovenous shunt for palliation of malignant ascites.Cancer 1982;49:600–2.
Holm A, Halpern NB, Aldrete JS. Peritoneovenous shunt for intractable ascites of hepatic, nephrogenic, and malignant causes.Am J Surg 1989;158:162–6.
Edney JA, Hill A, Armstrong D. Peritoneovenous shunts palliate malignant ascites.Am J Surg 1989;158:598–601.
Schwartzentruber D, Leapman SB, Filo RS, Madura JA. Thrombofibrinous sheath occlusion of peritoneovenous shunts.Surgery 1987;102:534–9.
Gough IR. Control of malignant ascites by peritoneovenous shunts.Cancer 1984;54:2226–30.
Souter RG, Tarin D, Kettlewell MGW. Peritoneovenous shunts in the management of malignant ascites.Br J Surg 1983;20:478–81.
Hayashi Y, Torisu M. New approach to management of malignant ascites with streptococcal preparation OK-432.Surg 1990;107:74–84.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schumacher, D.L., Saclarides, T.J. & Staren, E.D. Peritoneovenous shunts for palliation of the patient with malignant ascites. Annals of Surgical Oncology 1, 378–381 (1994). https://doi.org/10.1007/BF02303809
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303809